RxDoctor Payments Data

Lindsay Kelly

Family · Wilmington, DENPI 1265815526

Payments from drug & device makers

$2,995in general payments, 2019–2025

Across 180 payments — averaging $16.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$568
  • AstraZeneca$344
  • Pfizer$249
  • Lilly USA, LLC$215
  • Amgen$198
  • AbbVie$194
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$2,995100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,995 in reported general payments places this provider in the 85th percentile of 523 family providers in Delaware.

See all family providers in Delaware

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin66$74,882
OzempicSemaglutide72$68,111
FarxigaDapagliflozin Propanediol40$54,013
RybelsusSemaglutide22$44,765
EliquisApixaban43$37,438
XareltoRivaroxaban23$27,698
JanuviaSitagliptin Phosphate18$23,157
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$21,658
Repatha SureclickEvolocumab31$19,821
MounjaroTirzepatide11$19,112
LinzessLinaclotide14$11,414
AbrysvoRsv Vacc, Pref A And Pref B/Pf33$10,534
ShingrixVaricella-Zoster Ge/As01b/Pf33$7,300
Tresiba Flextouch U-100Insulin Degludec11$6,811
Lantus SolostarInsulin Glargine,hum.Rec.Anlog43$6,177

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$183$112,87594 claims
Boehringer IngelheimJardiance$128$74,88266 claims
AstraZenecaFarxiga$344$54,01340 claims
PfizerEliquis, Abrysvo$249$47,97376 claims
GSKTrelegy Ellipta, Shingrix$568$28,95855 claims
MerckJanuvia$192$23,15718 claims
Lilly USA, LLCMounjaro$215$19,11211 claims
AbbVieLinzess$194$11,41414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 523 family providers in Delaware.

Other family in Wilmington

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →